Huw M.  Nash net worth and biography

Huw Nash Biography and Net Worth

Huw Nash is the chief operating officer and chief business officer of Stoke Therapeutics and was previously the founding chief executive officer. An entrepreneur-in-residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing startup biotechnology companies. Prior to Stoke, Huw was a co-founder and vice president of corporate development for Aileron Therapeutics. He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as vice president of external collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in biochemical sciences from Harvard College and earned his Ph.D. in organic chemistry from Harvard University.

What is Huw M. Nash's net worth?

The estimated net worth of Huw M. Nash is at least $76,950.00 as of September 1st, 2021. Dr. Nash owns 5,700 shares of Stoke Therapeutics stock worth more than $76,950 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Nash may own. Additionally, Dr. Nash receives an annual salary of $429,670.00 as COO at Stoke Therapeutics. Learn More about Huw M. Nash's net worth.

How old is Huw M. Nash?

Dr. Nash is currently 57 years old. There are 7 older executives and no younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Huw M. Nash's age.

What is Huw M. Nash's salary?

As the COO of Stoke Therapeutics, Inc., Dr. Nash earns $429,670.00 per year. There are 3 executives that earn more than Dr. Nash. The highest earning executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who commands a salary of $931,210.00 per year. Learn More on Huw M. Nash's salary.

How do I contact Huw M. Nash?

The corporate mailing address for Dr. Nash and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Huw M. Nash's contact information.

Has Huw M. Nash been buying or selling shares of Stoke Therapeutics?

Huw M. Nash has not been actively trading shares of Stoke Therapeutics over the course of the past ninety days. Most recently, Huw M. Nash sold 3,800 shares of the business's stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $23.07, for a transaction totalling $87,666.00. Learn More on Huw M. Nash's trading history.

Who are Stoke Therapeutics' active insiders?

Stoke Therapeutics' insider roster includes Edward Kaye (), Huw Nash (COO), and Barry Ticho (Insider). Learn More on Stoke Therapeutics' active insiders.

Are insiders buying or selling shares of Stoke Therapeutics?

In the last twelve months, insiders at the sold shares 10 times. They sold a total of 119,227 shares worth more than $1,065,158.12. The most recent insider tranaction occured on March, 19th when CFO Stephen J Tulipano sold 4,116 shares worth more than $25,107.60. Insiders at Stoke Therapeutics own 12.3% of the company. Learn More about insider trades at Stoke Therapeutics.

Information on this page was last updated on 3/19/2024.

Huw M. Nash Insider Trading History at Stoke Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2022Sell3,800$23.07$87,666.00View SEC Filing Icon  
12/1/2021Sell5,700$24.44$139,308.00View SEC Filing Icon  
11/3/2021Sell1,900$25.00$47,500.00View SEC Filing Icon  
11/1/2021Sell3,800$23.54$89,452.00View SEC Filing Icon  
10/1/2021Sell5,700$24.83$141,531.00View SEC Filing Icon  
9/1/2021Sell5,700$26.00$148,200.005,700View SEC Filing Icon  
8/2/2021Sell5,700$28.87$164,559.00View SEC Filing Icon  
1/6/2021Sell32$57.14$1,828.48View SEC Filing Icon  
1/4/2021Sell5,700$58.97$336,129.00View SEC Filing Icon  
12/18/2020Sell50,000$60.00$3,000,000.0041,985View SEC Filing Icon  
12/1/2020Sell5,700$49.84$284,088.005,700View SEC Filing Icon  
11/10/2020Sell50,000$45.00$2,250,000.00
11/2/2020Sell5,700$37.21$212,097.005,700View SEC Filing Icon  
10/1/2020Sell5,700$34.54$196,878.005,700View SEC Filing Icon  
9/8/2020Sell30,718$30.00$921,540.0030,718View SEC Filing Icon  
9/1/2020Sell5,700$27.74$158,118.005,700View SEC Filing Icon  
8/28/2020Sell2,081$30.00$62,430.002,081View SEC Filing Icon  
7/16/2020Sell1,900$25.06$47,614.001,900View SEC Filing Icon  
7/7/2020Sell913$22.41$20,460.33View SEC Filing Icon  
7/1/2020Sell3,800$23.15$87,970.003,800View SEC Filing Icon  
6/1/2020Sell2,107$27.18$57,268.262,107View SEC Filing Icon  
3/2/2020Sell49,143$25.89$1,272,312.276,324View SEC Filing Icon  
See Full Table

Huw M. Nash Buying and Selling Activity at Stoke Therapeutics

This chart shows Huw M Nash's buying and selling at Stoke Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Stoke Therapeutics Company Overview

Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
Read More

Today's Range

Now: $13.50
Low: $12.20
High: $14.25

50 Day Range

MA: $6.07
Low: $4.12
High: $14.17

2 Week Range

Now: $13.50
Low: $3.35
High: $16.40

Volume

4,559,318 shs

Average Volume

2,266,374 shs

Market Capitalization

$625.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68